Thus, we show that both SGLT2 inhibitors and GLP-1 receptor agonists offer cardiovascular protection in T2DM, withSGLT2i providing a modest advantage in reducing MACE and a significant benefit in lowering heart failure hospitalizations. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.